Precision-Guided (MALT-Targeting) Mucosal Vaccines

          Rather than “playing our cards close to our chest”, we would prefer that every vaccine company, research group, and government agency know exactly what we are doing, why we are doing it that way, what we hope to do next, and what they can expect from us during 2026.

          That approach makes the most sense to us, in light of the following factors:

• We do NOT have any facilities, or expertise – or any desire, at any level – to begin testing actual pathogens, in any types of animals. Instead, all of the work we performed directly was in a “startup incubator lab,” which only allowed mice and rats to be tested, and which did not allow any actual pathogens to be tested, used, or brought into the labs; and, we aren't even renting that lab space any more, since the remaining work needs to be done in different types of facilities. 

• We have absolutely no desire to ever become a company which manufactures or sells any type of vaccine. Instead, we hope to become a licensing company, and a company that promotes and enables as much research as possible, as quickly as possible, into as many types of mucosal vaccines as possible, for as many different types of animals as possible. And, those goals and desires are indeed affected by, and consistent with, a set of entirely humanitarian, altruistic, and benevolent hopes and wishes. We want this technology to begin helping people find ways to minimize or completely avoid sickness, suffering, and disease, among animals as well as humans, and we want to do all we can, to help reduce and control healthcare costs.

• Although it is not a pressing goal at the moment, we also hope to eventually help lay a foundation for better, more useful, and more productive exchanges, between anti-vaxxers, and the scientific and medical communities. If these new types of mucosal vaccines can eliminate any need for the harsh and nasty adjuvants that injectable vaccines require, and can provide other important advantages as well, they may end up creating a “middle ground” where people on both sides of the pro-vax and anti-vax arguments can meet, and talk, and actually communicate with each other, rather than pointing fingers, making accusations, and trying to defend against and deny anything and everything “the other side” is doing, to “try to score points”.

 

So . . .  instead of wanting to compete against anyone, we hope to become a licensing company, which can:

• create a structure and system that will incentivize those who are already experts – in testing vaccines against actual pathogens, in one or more types of animals – to do those types of tests. How can we offer that encouragement and incentive? By both: (a) offering custom-engineered MALT-targeting T7 phage constructs, at low cost (we hereby commit to a $4000 price, for each of the first ten phage constructs, and we'll see what happens, after that), carrying any antigen sequence that a qualified requester will commit to actually testing, in “pathogen challenge tests”,  in one or more types of animals; and, (b) openly offering a worldwide exclusive license, to any and all use of our MALT-targeting delivery system, for any and all vaccines against a specific pathogen or disease, in one or more types of animals, to the first animal vaccine company, vet school research group, or other qualified group which generates “proof of efficacy” that is sufficiently solid and detailed to enable “registration” (i.e., authorization for sale for use in animals) by the U.S. Department of Agriculture, for the requesting company to sell that type of vaccine. As a more detailed statement of that approach, the next page contains a single-page handout we provided to any interested visitors, at the World Vaccine Congress 2026, held in Washington DC on March 30-April 2, 2026.

• create an advisory board – if the research in animal vaccines looks strong and promising – to begin evaluating suggestions and proposals from vaccine manufacturers, for how they would suggest moving forward to begin testing and making MALT-targeting human vaccines against various diseases. In other words, we don’t want to get ahead of ourselves, and we have made no decisions or commitments, of any sort, concerning human vaccines. Instead, if the animal work looks promising, we will begin talking with experienced people who have worked in or with the human vaccine industry, to get their advice, and possibly their support and/or participation; and, 

• begin talking with an organization called RADVAC, about whether and how some early small-scale clinical trials might be organized for doctors, nurses, and other health care workers, since they: (i) are highly and heavily exposed to new strains, mutants, and variants of both COVID and influenza, because of their work with infected patients; and, (ii) are in a position to make well-informed personal decisions, about whether they might wish to try and help test a mucosal vaccine against some new variant or mutant strain of either COVID or influenza, if that vaccine has been shown to create “neutralizing antibodies” of the “secreted mucosal IgA dimer” type, against some new and dangerous new strain of either type of virus. The RADVAC organization was formed in Boston by top-level biochemistry experts connected to Harvard and/or MIT (and, that work was funded mainly by internet billionaires with political attitudes that leaned in generally libertarian or at least highly pragmatic directions) soon after the COVID pandemic broke out in 2020, when the government announced that it might take up to two years before any effective COVID vaccines would become available. Those experts began working together to create the best oral vaccine they could create, to protect themselves and their loved ones, while waiting (or, “rather than merely waiting, passively”) for government-approved vaccines. So, they are worth talking with, to see what they learned from those efforts and experiences. And, if people who actively work in health care (and who are frequently exposed to infected patients) can be shown enough hard, solid, trustworthy data – focusing on both mucosal antibody formation, and apparent safety – to persuade and convince THEM that the types of mucosal vaccines described herein can probably help protect people who are being actively exposed to infected patients, then it's hard to see why others should try to stop experienced and educated “health-care professionals” from doing what they can, to protect themselves, and their families and friends.

 

          Stated in alternate words, we hope and intend to create a large number of licensing opportunities, for a substantial number of animal vaccine companies, in ways that (we hope) will end up creating a network of friends, allies, and partners, rather than creating enemies, adversaries, and opponents.